FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1) is expressed from human HEK293 cells. It contains AA Met 1 - Ala 54 (Accession # Q02223-1). It is the FITC labeled form of Human BCMA, His Tag (Cat. No. BCA-H522y).
FITC-Labeled Human BCMA, Fc Tag (Cat. No. BCA-HF254) is expressed from human HEK293 cells. It contains AA Met 1 - Ala 54 (Accession # Q02223-1). It is the FITC labeled form of Human BCMA, Fc Tag (Cat. No. BC7-H5254).
PE-Labeled Human BCMA, His Tag (BCA-HP2H2) is produced via site-specific conjugation of PE to Human BCMA, His Tag under optimal conditions with a proprietary technology. Human BCMA, His Tag is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 54 (Accession # Q02223-1).
FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with FMC63.
FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with FMC63.
FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1) is expressed from human HEK293 cells. It contains AA Met 1 - Ala 54 (Accession # Q02223-1). It is the FITC labeled form of Human BCMA, His Tag (Cat. No. BCA-H522y).